With dual approvals, Biohaven's migraine blockbuster-in-waiting snares nearly $500M in 2021

With dual approvals, Biohaven's migraine blockbuster-in-waiting snares nearly $500M in 2021fkansteinerThu, 01/06/2022 - 11:17